CAR T manufacturing and development continued to progress through early regulatory and deal announcements spanning autoimmune targeting and next-generation bivalent antigen designs. Hangzhou Qihan Biotech received FDA IND clearance for QT-019C, an allogeneic universal CAR T therapy for autoimmune diseases. The off-the-shelf product is engineered to stably express two distinct CARs targeting CD19 and BCMA, with the IND clearance enabling movement toward clinical initiation. Separately, Liminatus Pharma agreed to pay shares valued at $320 million to acquire InnocsAI, adding an oncology CAR T pipeline that includes an autologous CD19xCD22 bivalent CAR T (IBC101) already cleared to start a Phase 1/2 study at a hospital in Korea. The deal also brings preclinical programs involving a bicistronic CAR-T and additional antibody modules intended to broaden antigen coverage. Together, the items reflect continued investor appetite for next-generation CAR T designs—particularly multi-antigen strategies and universal approaches—as well as the importance of securing regulatory clearance to maintain development timelines.